Literature DB >> 18454307

Role of ErbB4 in breast cancer.

Maria Sundvall1, Kristiina Iljin, Sami Kilpinen, Henri Sara, Olli-Pekka Kallioniemi, Klaus Elenius.   

Abstract

Members of the ErbB subfamily of receptor tyrosine kinases are important regulators of normal mammary gland physiology, and aberrations in their signaling have been associated with breast tumorigenesis. Therapeutics targeting epidermal growth factor receptor (EGFR = ErbB1) or ErbB2 in breast cancer have been approved for clinical use. In contrast, relatively little is known about the biological significance of ErbB4 signaling in breast cancer. This review focuses on recent advances in our understanding about the role of ErbB4 in breast carcinogenesis, as well as in the potential clinical relevance of ErbB4 in breast cancer prognostics and therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18454307     DOI: 10.1007/s10911-008-9079-3

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  93 in total

1.  Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.

Authors:  C K Tang; X Z Concepcion; M Milan; X Gong; E Montgomery; M E Lippman
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

2.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

3.  WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.

Authors:  A K Bednarek; K J Laflin; R L Daniel; Q Liao; K A Hawkins; C M Aldaz
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

4.  Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.

Authors:  T Komurasaki; H Toyoda; D Uchida; S Morimoto
Journal:  Oncogene       Date:  1997-12-04       Impact factor: 9.867

5.  TACE is required for the activation of the EGFR by TGF-alpha in tumors.

Authors:  Maria Borrell-Pagès; Federico Rojo; Joan Albanell; Josep Baselga; Joaquín Arribas
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

Review 6.  ErbB4 and its isoforms: patentable drug targets?

Authors:  Ilkka Paatero; Klaus Elenius
Journal:  Recent Pat DNA Gene Seq       Date:  2008

7.  Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.

Authors:  Caroline J Witton; Jonathan R Reeves; James J Going; Timothy G Cooke; John M S Bartlett
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

8.  Association of Wwox with ErbB4 in breast cancer.

Authors:  Rami I Aqeilan; Valentina Donati; Eugenio Gaudio; Milena S Nicoloso; Maria Sundvall; Anna Korhonen; Johan Lundin; Jorma Isola; Marius Sudol; Heikki Joensuu; Carlo M Croce; Klaus Elenius
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

Review 9.  Amphiregulin: role in mammary gland development and breast cancer.

Authors:  Jean McBryan; Jillian Howlin; Silvia Napoletano; Finian Martin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-09       Impact factor: 2.673

10.  Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.

Authors:  Andrea Sassen; Justine Rochon; Peter Wild; Arndt Hartmann; Ferdinand Hofstaedter; Stephan Schwarz; Gero Brockhoff
Journal:  Breast Cancer Res       Date:  2008-01-08       Impact factor: 6.466

View more
  66 in total

Review 1.  E3 ubiquitin ligases in ErbB receptor quantity control.

Authors:  Kermit L Carraway
Journal:  Semin Cell Dev Biol       Date:  2010-09-22       Impact factor: 7.727

2.  ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

Authors:  Meghan M Morrison; Katherine Hutchinson; Michelle M Williams; Jamie C Stanford; Justin M Balko; Christian Young; Maria G Kuba; Violeta Sánchez; Andrew J Williams; Donna J Hicks; Carlos L Arteaga; Aleix Prat; Charles M Perou; H Shelton Earp; Suleiman Massarweh; Rebecca S Cook
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 3.  Targeting γ-secretase in breast cancer.

Authors:  Jianxun Han; Qiang Shen
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-06-21

Review 4.  Biological function of nuclear receptor tyrosine kinase action.

Authors:  Sungmin Song; Kenneth M Rosen; Gabriel Corfas
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-07-01       Impact factor: 10.005

Review 5.  HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.

Authors:  Frank E Jones
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-13       Impact factor: 2.673

6.  ErbB4 3'-UTR Variant (c.*3622A>G) is Associated with ER/PR Negativity and Advanced Breast Cancer.

Authors:  Maryam Tabatabian; Hamzeh Mesrian Tanha; Hossein Tabatabaeian; Samira Sadeghi; Kamran Ghaedi; Parisa Mohamadynejad
Journal:  Indian J Clin Biochem       Date:  2018-09-28

7.  Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.

Authors:  Jonathan W Haskins; Don X Nguyen; David F Stern
Journal:  Sci Signal       Date:  2014-12-09       Impact factor: 8.192

8.  Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides.

Authors:  Charlton Cooper; Jimin Guo; Yi Yan; Shilpa Chooniedass-Kothari; Florent Hube; Mohammad K Hamedani; Leigh C Murphy; Yvonne Myal; Etienne Leygue
Journal:  Nucleic Acids Res       Date:  2009-05-29       Impact factor: 16.971

9.  Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.

Authors:  Andrea Sassen; Simone Diermeier-Daucher; Manuela Sieben; Olaf Ortmann; Ferdinand Hofstaedter; Stephan Schwarz; Gero Brockhoff
Journal:  Breast Cancer Res       Date:  2009-07-22       Impact factor: 6.466

10.  The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene.

Authors:  Y L Chua; Y Ito; J C M Pole; S Newman; S-F Chin; R C Stein; I O Ellis; C Caldas; M J O'Hare; A Murrell; P A W Edwards
Journal:  Oncogene       Date:  2009-10-05       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.